Novartis-Backed Protego Eyes Pivotal Amyloidosis Study With $130M Series B

By /

Protego Biopharma is advancing a small-molecule drug that helps light chain proteins fold correctly, in turn addressing the underlying biological cause of AL amyloidosis.

Scroll to Top